Health Catalyst (HCAT) Misses Q3 EPS by 3c, provides guidance

Health Catalyst (NASDAQ: HCAT) reported Q3 EPS of $0.07, $0.03 worse than the analyst estimate of $0.10. Revenue for the quarter came in at $76.4 million versus the consensus estimate of $76.27 million.

GUIDANCE:

Health Catalyst sees Q4 2024 revenue of $78-84 million, versus the consensus of $80.656 million. Adjusted EBITDA between $6.8 million and $8.8 million

For the full year of 2024, we expect:

Total revenue between $305.0 million and $311.0 million, versus the consensus of $342.4

Adjusted EBITDA between $25.0 million and $27.0 million

For earnings history and earnings-related data on Health Catalyst (HCAT) click here.

You May Also Be Interested In

• Sandisk targets mid-to-high teens revenue growth through FY2030
• Bending Spoons S.p.A. (BSP) Tops Q2 EPS by 19c; offers guidance
• Azitra, Inc. (AZTR) Tops Q2 EPS by 54c